milvexian
bms,Janssen
['factor xi', 'cardio', 'milvexian']
the new factor xi inhibitor antithrombotic, milvexian, has shown promising results in a dose-finding phase 2 trial in patients with acute ischemic stroke or tia, when given in addition to dual antiplatelet therapy. #esccongress #cardiotwitter 
theheartorg | Medscape Cardiology is your best source for cardiovascular disease news online. https://t.co/Q8t8IR82zV